Royal Holloway University of London

Royal Holloway is one of the UK’s leading research-intensive universities, with 19 academic departments spanning the arts and humanities, sciences, social sciences, management and economics. As the UK’s most international university, we combine world-class research with a global perspective, yet at the same time our campus has an intimate human scale. This means our students learn from internationally-renowned academics and researchers while also being known by name themselves.

Royal Holloway takes its name from our Founder, the Victorian entrepreneur Thomas Holloway, who established Royal Holloway as a college for women in 1886. Holloway was not the first visionary to realise the benefits of an education for women; Elizabeth Jesser Reid, a pioneering social reformer, founded Bedford College in 1849 as the UK’s first ever women’s college. The two institutions merged in 1985 and their combined strength and history has made Royal Holloway the world-leading university it is today. These far sighted Victorians not only left us our extraordinary Founder’s Building and a history of academic ‘firsts’; their spirit also lives on in our values and culture – to challenge convention, break new ground and make learning an adventure.

Royal Holloway is a research leader and is acknowledged worldwide for high quality research across all sectors of the arts, humanities and sciences. This is built on a long track-record of pioneering research, continued investment in top-class staff and facilities and innovative partnerships in Higher Education, Government, industry and other organisations in the UK and abroad. We continue to compete successfully for first-class academics with new perspectives and expertise. Their cutting-edge research makes our courses compelling and enables us to make a greater impact on society. We were recently recognised as no.1 in the UK for both research influence (citations, 11th in the world) and for international outlook (6th in the world),  (Times Higher Education World University Rankings 2014-15).

London Higher Europe Contact:

Alicen Nickson, Director of Research and Enterprise 
+44 (0)1784 443844


Dr Jakke Tamminen

ADAPT: the Adoption of New Technological Arrays in the Production of Broadcast Television

ADAPT is a five-year (2013-2018) research project, funded by the European Research Council and based at Royal Holloway, University of London. The aim of the project is to research and document the history of British broadcast television technology between 1960 and the near-present. Television has seen vast technological changes since 1960. In 1960, the revolutionary technologies were two-inch videotape and 16mm film with synched tape-recorded sound. Tape and film editing gave way to non-linear post-production in the 1990s. Now we have tapeless production in high definition. All these changes have affected what has appeared on the screen. It also affected the lives of skilled technicians, who sometimes had to adapt to new ways of working, and just as often took a hand in adapting the available equipment to their specific needs. ADAPT will now draw together the threads of this complex story. This is important now that archival television footage...

Oral Vaccination against Clostridium difficile Infection (CDVAX)

The CDVAX project addresses a bacterial nosocomial pathogen, Clostridium difficile, of significant importance to Europe for four clear reasons: The bacterium carries multiple drug resistance that has been shown to transfer from strain to strain and from animals to humans Control of the disease in humans requires an extensive regimen of antibiotics The disease produces four-times as many mortalities as MRSA and is the leading hospital-acquired infection There is currently no marketed vaccine, or development stage vaccine able to prevent both primary infection and relapse Current vaccine strategies under development are based on injection of bacterial toxoids, a classical systemic approach. While some efficacy is seen it is now accepted that to effectively vaccinate against C. difficile infection (CDI) the vaccine must confer the induction of mucosal antibodies at the site of infection and induce an immune response able to decolonise C. difficile from the gastrointestinal (GI) tract. Decolonisation is necessary to prevent recurrence of...